Astrocytoma Follow-up

Updated: Dec 21, 2018
  • Author: Benjamin C Kennedy, MD; Chief Editor: Herbert H Engelhard, III, MD, PhD, FACS, FAANS  more...
  • Print

Further Outpatient Care

Outpatient management includes the following:

  • Patients should consult a neurologist to observe the progression of neurological signs and symptoms and to manage steroid and anticonvulsant regimens

  • Outpatient neurosurgery observation is necessary for tumor monitoring and management of hydrocephalus if a shunt has been placed

  • Postoperative and postirradiation chemotherapy trials using nitrosourea and other agents are likely to benefit patients with malignant astrocytomas, but the benefit for patients with well-differentiated astrocytomas is questionable

  • Frequency of postoperative MRIs is determined by both the neurosurgeon and other physicians involved in the ongoing care of the patient, including the neurooncologist and radiation oncologist


Further Inpatient Care

Management of low-grade astrocytomas is controversial. The tumors may be radiographically stable and clinically quiescent for long periods after the initial presentation.

Therapeutic options include observation, radiation, and resection with and without radiation. Unless an astrocytoma is resected completely, radiation therapy should be considered. In higher-grade lesions, even if gross total resection is confirmed radiographically, postoperative radiation therapy is indicated because microscopic disease remains. If no resection is undertaken and radiation is contemplated, a stereotactic biopsy is recommended to establish the histological grade of the tumor definitively.


Inpatient & Outpatient Medications





See the list below:

  • If surgery is anticipated, patients should be transferred to institutions with an appropriately equipped and adequately staffed neurosurgical intensive care unit for postoperative monitoring.

  • Patients may require extensive or focused postoperative rehabilitation that may necessitate transfer to specialized institutions dedicated to physical and occupational therapy.



Although neurological injury (potentially devastating) and death are possible sequelae of operative intervention, neurosurgery for astrocytomas is generally intended to decrease tumor bulk while avoiding permanent neurological injury. Transient deficits due to local swelling or injury may occur, but they often improve after a course of physical therapy and rehabilitation.



Prognosis for survival after operative intervention and radiation therapy can be favorable for low-grade astrocytomas. For low-grade lesions, the mean survival time after surgical intervention has been reported as 6-8 years. For those patients who undergo surgical resection, the prognosis depends on whether the neoplasm progresses to a higher-grade lesion.

In the case of anaplastic astrocytoma, symptomatic improvement or stabilization is the rule after surgical resection and irradiation. High-quality survival is observed in 60-80% of these patients. Factors such as youth, functional status, extent of resection, and adequate irradiation affect the duration of postoperative survival.

Irradiation of incompletely resected tumors can increase 5-year postoperative survival rates from 0-25% for low-grade astrocytomas and from 2-16% for anaplastic astrocytomas. Furthermore, the median survival rate of patients with anaplastic astrocytoma who undergo both resection and irradiation has been reported to be twice that of patients receiving only operative therapy (5 y vs 2.2 y).

Attempts have been made to determine prognosis and response to various treatment modalities based on the individual pattern of genetic changes in a particular tumor. For example, patients with oligodendrogliomas that exhibit chromosomal changes at band 1p19q are known to have better responses to the procarbazine, lomustine (CCNU), vincristine (PCV) regimen of chemotherapy.

Efforts are under way to identify similar unique susceptibilities associated with other commonly altered genes and proteins in astrocytomas. Other groups are working on developing models that will allow for a more accurate assessment of prognosis based on a combination of molecular profiling of the tumors and clinical characteristics of the patient. [54]

In high-grade astrocytoma, elevations in glioblastoma kallikrein 6 (KLK6), kallikrein 7 (KLK7), and kallikrein 9 (KLK9) proteins may have prognostic utility as markers of patient survival. Kallikrein levels and associated outcomes were as follows [55] :

  • Elevated KLK6- or KLK7-IR – Poor patient prognosis
  • Increased percent of tumor immunoreactive for KLK6 or KLK9  – Decreased survival
  • KLK6 immunoreactivity score < 10, KLK6 < 3% tumor core stained, or KLK7 immunoreactivity score < 9 – Significantly improved survival

Survivors of pediatric astrocytoma are at high risk for long-term complications of the disease and its treatment. An evaluation of 1182 astrocytoma survivors by Effinger et al found that at 30 years after diagnosis, compared with their siblings, survivors were at increased risk of serious chronic conditions and reported higher rates of poor general health, poor mental health, functional impairment, and activity limitation, as well as lower rates of college graduation, marriage, employment, and household income. [56]